Subscribe to NRx Newsletter

lawsuit

NRx Press Release
Jun. 22, 2022
Class Action Suit Against NRx Pharmaceuticals Dismissed

NRx Pharmaceuticals, Inc. is pleased to announce that on June 13, 2022, the plaintiffs in the securities class action lawsuit captioned “Dal Bosco v. NRx Pharmaceuticals, Inc. et al.” filed a notice in the U.S. District Court for the District of Delaware voluntarily dismissing the action against NRx Pharmaceuticals and its former officers.  The dismissal was made without prejudice.

Read More
NRx Press Release
Jan. 14, 2022
NRx Responds to Relief’s Allegations of January 14, 2022

Neither NRx nor Jonathan Javitt accused current Relief management or board of a criminal past. The lawsuit identifies FINRA actions against Dr. Sevelraju, prior securities investigation, and civil fines against Dr. John Paul Waymack, and a prior securities fraud conviction, incarceration, and SEC fines against Adam Gottbetter. NRx provided all financial records to Relief on […]

Read More